TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01453023
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Study: NCT03458559
Drug: Rhenium-188-HEDP
Normalized name: RHENIUM
DrugBank: Rhenium re-186 (DB19266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
Study: NCT03184090
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib in combination with endocrine therapy (investigator's choice)
Study: NCT01453023
Drug: Fluticasone Furoate/Vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Study: NCT01330693
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
Study: NCT01755676
Drug: Orlistat 60 mg
Normalized name: orlistat 60 MG
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet 3 times a day
Study: NCT01330693
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-active sugar pill randomly assigned at baseline visit
Study: NCT00003415
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02232399
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Study: NCT02232399
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Study: NCT01660256
Drug: OPC-12759
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation, 4 times/day for 4 weeks
Study: NCT00637468
Drug: Intravenous injection of acetazolamide
Normalized name: acetazolamide Injection
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003415
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01440127
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
Study: NCT04468230
Drug: Nicotine Transdermal Patch
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Treatment Condition
Study: NCT00601432
Drug: levofloxacin oral solution
Normalized name: Levofloxacin Oral Solution
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02361060
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mcg/kg
Study: NCT02361060
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg/kg
Study: NCT02361060
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mcg/kg
Study: NCT00167232
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01150461
Drug: losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50 mg b.i.d
Study: NCT04230460
Drug: Cannabis (THC) (Inhaled) Placebo
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
Study: NCT04230460
Drug: Cannabis (High% THC) (Inhaled)
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
Study: NCT04230460
Drug: Cannabis (Very High% THC) (Inhaled)
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
Study: NCT04230460
Drug: Alcohol (oral)
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
Study: NCT04062435
Drug: Drop application in the inferior fornix
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arms
Study: NCT04062435
Drug: Drop application on the cornea
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arms
Study: NCT02706951
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; Oral
Study: NCT02706951
Drug: Placebo Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; Oral
Study: NCT00494468
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03080142
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
Study: NCT03080142
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
Study: NCT02614612
Drug: Itacitinib (200 mg)
Normalized name: ritlecitinib 50 MG
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02614612
Drug: Itacitinib (300 mg)
Normalized name: ritlecitinib 50 MG
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02614612
Drug: prednisone or methylprednisolone (corticosteroids)
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
Study: NCT01743690
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01743690
Drug: fluocinolone
Normalized name: Fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01841697
Drug: Omarigliptin
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
Study: NCT01841697
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg oral tablet once a day for 24 weeks
Study: NCT01841697
Drug: Placebo to omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
Study: NCT01841697
Drug: Placebo to Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
Study: NCT01841697
Drug: Open-label Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
Study: NCT01841697
Drug: Open-label Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
Study: NCT00678483
Drug: rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: once daily
Study: NCT00511186
Drug: BIAP
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
Study: NCT04961632
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
Study: NCT04961632
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
Study: NCT00996502
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle
Study: NCT00996502
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg of Bevacizumab every 3 weeks
Study: NCT00996502
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of Erlotinib PO daily days 2-16
Study: NCT00996502
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg of Prednisone PO bid
Study: NCT00302159
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
Study: NCT00302159
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
Study: NCT02790775
Drug: Anti-VEGF in quadrant 1
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02790775
Drug: Anti-VEGF in quadrant 2
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02790775
Drug: Anti-VEGF in quadrant 3
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02790775
Drug: Anti-VEGF in quadrant 4
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00549978
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cilostazol, then cilostazol/probucol
Study: NCT00549978
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol probucol/ cilostazol
Study: NCT01008163
Drug: YY-351
Normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT04374383
Drug: Phthalocyanine Dye
Normalized name: amaranth dye
DrugBank: Phthalocyanine (DB12983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
Study: NCT04374383
Drug: LASER assisted SRP
Normalized name: SRP-6004
DrugBank: SRP-6004 (DB16998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASER assisted SRP will be carried
Study: NCT01408810
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
Study: NCT01241006
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
Study: NCT01241006
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 60mg PO q day for 5 days
Study: NCT02632812
Drug: Rebamipide effervescent granules
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Study: NCT02757313
Drug: Low dose THC marijuana
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02757313
Drug: High dose THC marijuana
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00909532
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150-mg tablets given orally q12h for up to 48 weeks
Study: NCT03874936
Drug: Dexamethasone 24mg Solution for Injection
Normalized name: dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administrated i.v.
Study: NCT00369096
Drug: bemiparin 3500 IU/day
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02063581
Drug: ipatasertib (Capsule)
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered single dose of Ipatasertib formulated as a capsule.
Study: NCT02063581
Drug: ipatasertib (Tablet)
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered single dose of Ipatasertib formulated as a tablet.
Study: NCT03153813
Drug: capsaicin 8% patches (Qutenza)
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01691547
Drug: UMEC
Normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
Study: NCT01691547
Drug: VI
Normalized name: VIG
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
Study: NCT01691547
Drug: FF
Normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
Study: NCT00571896
Drug: Senna+ docusate
Normalized name: DOCUSATE/SENNA
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
Study: NCT01743976
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: donepezil 5 mg once daily for 6 weeks
Study: NCT01495910
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
Study: NCT03226301
Drug: Ibrutinib until progression/relapse
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420mg ibrutinib daily until progression/relapse
Study: NCT03226301
Drug: Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28
Study: NCT04355936
Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm will receive standard care.
Study: NCT02654093
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02654093
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02654093
Drug: Cholecalciferol and Raloxifene co-administration
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02406989
Drug: MS-553
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT00818064
Drug: anti-IL-20
Normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single s.c. injection (per dose cohort)
Study: NCT00105105
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02759926
Drug: Denatonium benzoate
Normalized name: Denatonium Benzoate
DrugBank: Denatonium (DB18588)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02759926
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02928211
Drug: Aftobetin-HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
Study: NCT02165826
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast tablets
Study: NCT02165826
Drug: Roflumilast Placebo
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast placebo-matching tablets
Study: NCT02392104
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
Study: NCT02321267
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
Study: NCT02581059
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
Study: NCT01299142
Drug: FGI-101-1A6
DrugBank: GI-101 (DB17243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-TSG101 human monoclonal antibody, single dose
Study: NCT03421639
Drug: Aromatase and GnRH analog (11.25mg Leuprolide acetate)
Normalized name: leuprolide acetate 11.25 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 11.25mg only one
Study: NCT01002664
Drug: MCS-2
Normalized name: MC-3
DrugBank: TMC-310911 (DB15623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day (two 15 mg capsules) Qd for 12 weeks
Study: NCT01066715
Drug: XOMA 052
Normalized name: XomaZyme 791
DrugBank: XomaZyme-791 (DB17216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution subcutaneously administered monthly for 6 months
Study: NCT04451837
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ozempic s.c. once weekly for 6 months
Study: NCT04451837
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forxiga 10 mg p.o. once daily for 6 months
Study: NCT01262092
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
Study: NCT03833895
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25ug/kg/min phenylephrine during Cesarean Section Operation
Study: NCT03833895
Drug: Ringer's Solution
Normalized name: Ringer's solution
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml/kg/min of LR was administrated according to standard weight.